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Lifetime cost effectiveness of simvastatin in a range of risk groups
and age groups derived from a randomised trial of 20 536 people
Heart Protection Study Collaborative Group
Abstract
Objectives To evaluate the cost effectiveness of 40 mg
simvastatin daily continued for life in people of different ages
with differing risks of vascular disease.
Design A model developed from a randomised trial was used
to estimate lifetime risks of vascular events and costs of
treatment and hospital admissions in the United Kingdom.
Setting 69 hospitals in the UK.
Participants 20 536 men and women (aged 40-80) with
coronary disease, other occlusive arterial disease, or diabetes.
Interventions 40 mg simvastatin daily versus placebo for an
average of 5 years.
Main outcome measures Cost effectiveness of 40 mg
simvastatin daily expressed as additional cost per life year
gained. Major vascular event defined as non-fatal myocardial
infarction or death from coronary disease, any stroke, or
revascularisation procedure. Results were extrapolated to
younger and older age groups at lower risk of vascular disease
than were studied directly, as well as to lifetime treatment.
Results At the April 2005 UK price of £4.87 (€7; $9) per 28 day
pack of generic 40 mg simvastatin, lifetime treatment was cost
saving in most age groups and vascular disease risk groups
studied directly. Gains in life expectancy and cost savings
decreased with increasing age and with decreasing risk of
vascular disease. People aged 40-49 with 5 year risks of major
vascular events of 42% and 12% at start of treatment gained
2.49 and 1.67 life years, respectively. Treatment with statins
remained cost saving or cost less than £2500 per life year
gained in people as young as 35 years or as old as 85 with 5
year risks of a major vascular event as low as 5% at the start of
treatment.
Conclusions Treatment with statins is cost effective in a wider
population than is routinely treated at present.
Introduction
Large randomised trials have shown that lowering blood
concentrations of low density lipoprotein cholesterol with statins
greatly reduces rates of heart attacks, strokes, and revascularisa-
tion procedures in a wide range of people at high risk, largely
irrespective of their cholesterol concentrations and other
characteristics at presentation.1 The heart protection study has
shown that, especially when cheaper generic versions are used,
40 mg simvastatin daily is cost effective for a wider range of peo-
ple with vascular disease or diabetes than previously thought.2
That analysis only estimated cost effectiveness during the study
treatment period and did not provide estimates of the additional
costs per life year or quality adjusted life year gained.3
The present report extends this previous work in two ways.
Firstly, a model was developed and validated that allowed
extrapolation beyond the five year treatment period in the heart
protection study and estimation of lifetime cost per life year
gained and per quality adjusted life year gained; this facilitates
comparison with other potential uses of healthcare resources.
Secondly, these estimates were projected beyond the levels of risk
of vascular disease and age represented in the study to provide
guidance on the cost effectiveness of statins in a wider spectrum
of people.
Methods
We used data from the 20 536 participants in the heart
protection study to develop a Markov disease state transition
model. Participants were men and women who presented at
40-80 years with total cholesterol concentrations of at least 3.5
mmol/l (135 mg/dl) and a medical history of coronary disease,
cerebrovascular disease, other occlusive arterial disease, diabetes
mellitus, or (if a man aged ≥ 65) treated hypertension.4 Figure 1
is a schematic representation of the model, which is based
around the prediction of four key events. The annual risks of
occurrence of three main adverse events (“death from vascular
cause” defined as death from coronary disease, fatal stroke, or
other vascular event; “non-fatal major vascular event” defined as
non-fatal myocardial infarction, non-fatal stroke, or arterial
revascularisation; and “other vascular event” defined as
admission for angina, heart failure, or other cardiac or vascular
problem) were estimated as functions of baseline risk factors,
allocation to statin treatment, and within-study experience of
vascular events. During the course of the heart protection study,
some participants allocated simvastatin stopped taking statin
therapy (18% by the end of the study) and some participants
allocated placebo started taking non-study statin (32% by the
end).4 To assess the full effects of actually taking simvastatin, the
risk equations in the model incorporated a factor for the
proportion of full compliance seen between the treatment arms.
The effect of statin therapy used in the model was specific to
each vascular event category, with the same effect fitted for first
and subsequent events in the same category. We estimated the
fourth event in the model (mortality rate for non-vascular
causes) by removing deaths due to vascular causes from official
life table data for the United Kingdom.5–7 Allocation to 40 mg
simvastatin daily was not associated with any significant excess of
reported muscle symptoms (including a non-significant annual
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excess myopathy rate of 0.01%; P = 0.2) or of other adverse
events.4 Thus, such adverse events were not included in the cur-
rent analyses.
We used the model to predict the annual occurrence of death
due to vascular or non-vascular causes; of non-fatal major vascu-
lar events; or of other vascular events and the annual costs of
hospital admissions for such events in people taking or not tak-
ing 40 mg simvastatin daily. Annual costs of hospital admissions
(2001 UK prices) were estimated from data on hospital
admission in the heart protection study2 on the basis of age, sex,
disease history, other baseline characteristics, and vascular events
or death within the study. Treatment affected the risk of an event
occurring, but we found no evidence that it affected costs of hos-
pital admissions once the event had occurred. Annual rates of
vascular events predicted by the model were internally validated
against the rates seen during the five year follow-up in the heart
protection study for the proportion of participants taking statin
in each group and the average difference in low density lipopro-
tein cholesterol seen during the study. The model was then used
to project events and costs beyond the five year scheduled treat-
ment period and to estimate lifetime cost effectiveness of 40 mg
simvastatin daily versus no statin treatment among people of dif-
ferent ages and with different underlying risks of vascular events.
In the main analysis, we used the UK tariff price of £4.87 (€7; $9)
at which pharmacies were reimbursed for 28 days of treatment in
April 2005.8 Future life years and costs were discounted at an
annual rate of 3.5%.9
As in previous analyses,2 participants were divided into five
similar sized groups of estimated five year risk of a major vascu-
lar event, with average risks in the groups ranging from 12% to
42% (which correspond to risks of 4% to 12% for non-fatal myo-
cardial infarction or coronary death). These risk groups were
subdivided by age at entry to the study (40-49, 50-59, 60-69, and
≥ 70) to allow for the opposing effects of age on disease risk and
life expectancy. Parameter uncertainty in the estimates of life
years gained, cost savings in hospital stay, and cost per life year
gained was assessed by non-parametric bootstrapping.10 We also
examined several other scenarios. Firstly, predicted life
expectancy was adjusted for age specific and sex specific health
related quality of life derived from a representative sample of the
UK population11 12; secondly, it was related to only five years’ use
of generic simvastatin; and thirdly, it was related to lifetime use of
proprietary simvastatin (2005 UK price of £29.69 for 28 days).13
Finally, the model was extrapolated to older and younger age
groups and to people at lower risk of vascular disease than those
included in the heart protection study. Age at start of treatment
was projected to five years beyond the eligibility limits of the
study (down to 35 and up to 85), and risk was projected down to
a 5% risk of a major vascular event within five years (compared
with the 12% five year risk in the fifth with the lowest risk in the
heart protection study). See bmj.com for a technical appendix
containing additional details of the methods and model
validation, along with a further scenario related to diminishing
long term compliance with treatment.
Results
Internal validation of the Markov state transition model
Annual rates of death from vascular disease, of major vascular
events, and of all vascular events estimated from the state transi-
tion model (fig 1) were similar to those seen during the heart
protection study, as were the differences in rates (see technical
appendix on bmj.com). Figure 2 shows the similarity between
predicted and observed differences in the annual rates of first
and subsequent non-fatal major vascular events or deaths from
vascular disease during the five year treatment period (especially
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Fig 1 Schematic of the state transition model
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Fig 2 Observed (95% confidence interval) and predicted difference in annual
rates of major vascular events or deaths from vascular causes between groups
allocated to placebo and simvastatin in the heart protection study. LDL=low
density lipoprotein
Table 1 Predicted life years gained (95% confidence interval) by full compliance with lifetime use of 40 mg simvastatin daily for the population of the heart
protection study (not discounted)
Age at start (years)
Five year risk of major vascular event at start of treatment
12% 18% 22% 28% 42%
40-49 1.67 (0.84 to 2.47) 2.02 (1.13 to 2.85) 2.21 (1.27 to 3.07) 2.41 (1.45 to 3.26) 2.49 (1.55 to 3.36)
50-59 1.32 (0.66 to 2.00) 1.52 (0.82 to 2.22) 1.67 (0.94 to 2.40) 1.84 (1.07 to 2.60) 1.94 (1.18 to 2.68)
60-69 0.95 (0.47 to 1.47) 1.06 (0.55 to 1.62) 1.17 (0.63 to 1.74) 1.27 (0.71 to 1.86) 1.39 (0.82 to 1.99)
≥70 0.64 (0.31 to 0.98) 0.72 (0.36 to 1.11) 0.79 (0.41 to 1.19) 0.88 (0.48 to 1.29) 0.98 (0.56 to 1.39)
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when the average low density lipoprotein cholesterol difference
during the preceding 18 months was used in the model).
Cost effectiveness of simvastatin for the study population
We used the model to estimate the life expectancy and costs
associated with lifetime treatment with 40 mg simvastatin daily.
On the basis of full compliance, relative reductions in the risk of
death from vascular disease by 25%, of a non-fatal major vascu-
lar event or vascular death by 32%, and of any vascular event by
24% were derived from the risk equations. Table 1 shows the
undiscounted estimated gains in life expectancy among the par-
ticipants subdivided into fifths of five year risk of a major vascu-
lar event and by age at the start of treatment. The estimated life
years gained ranged between 0.64 years for people aged over 70
with a 12% five year risk of a major vascular event and 2.49 years
for those aged 40-49 with a 42% five year risk. Table 2 shows the
estimates for discounted life years gained, costs of statin
treatment, cost savings for hospital admissions, and costs per life
year gained. At £4.87 per 28 day pack of treatment, generic 40
mg simvastatin daily was cost saving for most of the risk and age
categories in the heart protection study; that is, the reduced costs
of hospital admissions as a result of fewer vascular events
outweighed the increased costs of statin treatment in all but one
category (£80 per life year gained for people aged ≥ 70 years at
the start with a 12% five year risk; table 2). The upper limits of the
95% confidence intervals for all risk and age groups were below
£1000 per life year gained (table A on bmj.com).
The heart protection study did not collect information on
quality of life, so evaluation of cost per quality adjusted life year
gained involved using data from a representative sample of the
UK population to adjust for age specific and sex specific health
related quality of life.11 12 Quality of life adjusted estimates for
lifetime use of generic 40 mg simvastatin daily were similar to the
unadjusted estimates (table 3). Estimated costs per life year
gained with only five years’ use of generic 40 mg simvastatin
daily were also similar to those for lifetime treatment, with both
costs and benefits reduced proportionally (table 4). Cost
effectiveness estimates were favourable even with proprietary 40
mg simvastatin at £29.69 per 28 day pack (table 4).
Table 2 Outcome measures with full compliance with lifetime use of
generic 40 mg simvastatin daily for the population of the heart protection
study
Outcome
Five year risk of major vascular event at start of treatment
12% 18% 22% 28% 42%
Life years gained
Age at start
(years):
40-49 0.62 0.81 0.94 1.08 1.24
50-59 0.58 0.71 0.82 0.94 1.08
60-69 0.50 0.58 0.66 0.75 0.88
≥70 0.38 0.45 0.50 0.57 0.68
Lifetime cost (£) of treatment with simvastatin
Age at start
(years):
40-49 1180 1100 1050 990 880
50-59 1030 950 900 860 760
60-69 840 780 730 680 590
≥70 670 620 580 540 460
Cost (£) of hospital admission due to simvastatin*
Age at start
(years):
40-49 −1450 −1810 −1970 −2080 −2100
50-59 −1250 −1400 −1460 −1570 −1530
60-69 −920 −980 −990 −1010 −950
≥70 −640 −650 −660 −650 −560
Cost (£) per life year gained
Age at start
(years):
40-49 −440 −880 −990 −1010 −990
50-59 −370 −630 −680 −760 −720
60-69 −140 −360 −400 −440 −400
≥70 80 −70 −160 −190 −140
Negative values indicate cost savings. £1=€1.5=$1.9.
All results discounted at 3.5% per annum; 28 day pack of generic simvastatin at £4.87.
Table 3 Additional scenarios of full compliance with 40 mg simvastatin
daily within the population of the heart protection study. Values are life
years gained unless stated otherwise
Treatment
Five year risk of major vascular event at start of treatment
12% 18% 22% 28% 42%
Lifetime use of generic simvastatin*
Age at start (years):
40-49 0.47 0.63 0.72 0.84 0.97
50-59 0.43 0.54 0.63 0.72 0.83
60-69 0.36 0.43 0.50 0.56 0.66
≥70 0.27 0.33 0.37 0.43 0.51
5 year use of generic simvastatin
Age at start (years):
40-49 0.09 0.13 0.17 0.21 0.29
50-59 0.11 0.15 0.19 0.23 0.32
60-69 0.13 0.17 0.20 0.25 0.35
≥70 0.14 0.17 0.20 0.24 0.34
Lifetime use of proprietary simvastatin
Age at start (years):
40-49 0.62 0.81 0.94 1.08 1.24
50-59 0.58 0.71 0.82 0.94 1.08
60-69 0.50 0.58 0.66 0.75 0.88
≥70 0.38 0.45 0.50 0.57 0.68
*Values are quality adjusted life years gained (adjusted for age specific and sex specific
health related quality of life).
All results discounted at 3.5% per annum.
Table 4 Cost (£) per life year gained (unless stated otherwise) for various
scenarios of full compliance with 40 mg simvastatin daily for the population
of the heart protection study
Treatment
Five year risk of major vascular event at start of treatment
12% 18% 22% 28% 42%
Lifetime use of generic simvastatin*
Age at start (years):
40-49 −580 −1140 −1280 −1310 −1270
50-59 −500 −830 −890 −990 −930
60-69 −200 −480 −530 −580 −530
≥70 110 −100 −220 −250 −190
5 year use of generic simvastatin
Age at start (years):
40-49 −1230 −1890 −2030 −2050 −1930
50-59 −1010 −1330 −1380 −1470 −1350
60-69 −600 −840 −870 −900 −800
≥70 −240 −410 −500 −520 −410
Lifetime use of proprietary simvastatin
Age at start (years):
40-49 9260 6010 4710 3620 2610
50-59 8720 6170 4900 3870 2860
60-69 8470 6430 5230 4190 3040
≥70 8910 6910 5740 4610 3340
*Values are adjusted for age specific and sex specific health related quality of life.
Negative values indicate cost savings. £1=€1.5=$1.9.
All discounted at 3.5% per annum; 28 day pack of generic simvastatin at £4.87 and
proprietary simvastatin at £29.69.
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Cost effectiveness of simvastatin beyond the study
population
The heart protection study comprised people presenting at
40-80 years with five year risks of a major vascular event in five
similar sized categories ranging from 12% to 42%. Extrapola-
tions indicate that lifetime use of generic 40 mg simvastatin daily
is cost effective for people below and above this age range with
five year risk of a major vascular event as low as 5% (tables 5 and
6). The estimated costs per life year gained ranged from about
£450 to £2500 for people with a 5% five year risk of a major vas-
cular event aged between 35 and 85 at the start of treatment.
Adjusting for age specific and sex specific quality of life did not
affect these conclusions; the cost per quality adjusted life year
gained was either a saving or less than £4000 across the
extended age groups and risk categories for vascular events con-
sidered (table 6).
Discussion
As well as preventing heart attacks and coronary death, statins
have been shown to reduce the incidence of ischaemic strokes,
and arterial revascularisation procedures.1 4 14 Recent guidelines,
therefore, recommend statins for patients at risk of all such
major vascular events, not just coronary events.15 16 In the UK,
statins are recommended for people with an estimated 10 year
risk of a cardiovascular event of 20% or more.17 18 But a large
meta-analysis has shown that similar relative reductions in risk
are produced by lowering low density lipoprotein cholesterol
with statins by the same absolute amount in higher and lower
risk populations.1 The present analyses indicate that, at current
generic prices, the initiation of lifetime treatment with simvasta-
tin is cost saving or very cost effective for people aged 35-85 with
risks of major vascular events as low as 1% per annum (that is,
about half the risk threshold proposed by the National Institute
for Health and Clinical Excellence; NICE). The estimated costs
per life year gained in all these people were lower than those
generally considered by NICE to be a cost effective use of health
resources.19
The heart protection study did not collect data on the quality
of life of participants. But, after adjusting for age specific and sex
specific health related quality of life derived from the UK popu-
lation, the estimated costs per quality adjusted life year from life-
long treatment with generic simvastatin remained highly
favourable across the extended age and risk groups considered.
Sensitivity analyses also indicated that lifetime and five year
treatment with generic simvastatin would be similarly cost effec-
tive for the populations studied. Lifelong use in these groups
even seemed to be cost effective at the much higher UK propri-
etary price; these results are relevant to countries where simvas-
tatin is more expensive. Although hospital outpatient costs and
primary care costs were not measured, including such costs
would be unlikely to alter the main conclusions of our analysis
given their comparatively low level.20 Muscle symptoms were sys-
tematically sought in the heart protection study; compared with
placebo, allocation to 40 mg simvastatin daily was not associated
with significantly more reports of muscle symptoms or, more
seriously, more cases of myopathy or rhabdomyolysis.4 Although
patients and doctors need to be aware that serious muscle prob-
lems can occur rarely,21 this does not materially affect the cost
effectiveness of routine statin use.
The lifetime extrapolation was based on a model developed
by using individual participant data from the five year treatment
period of the heart protection study. The vascular event rates
predicted by the model were comparable to the rates seen during
the within-study period. Similar reductions in relative risk with
statin therapy were modelled over time, including beyond the
study treatment period, because currently available evidence
shows that the relative effects are similar in different age groups
and during each successive year of treatment, without evidence
that the benefits are lost when treatment stops.1 22
Conclusion
At current UK prices for generic simvastatin, 40 mg simvastatin
daily is likely to be cost saving, or would cost less than £2500 per
life year gained, for people with an annual risk of major vascular
events of 1% or more, independently of their age at the start of
treatment. Hence, statin therapy should be considered routinely
Table 5 Life years gained by full compliance with lifetime use of generic 40
mg simvastatin daily projected beyond the population of the heart protection
study
Outcome
Five year risk of major vascular event at start of
treatment
5% 10% 20% 40%
Life years gained
Age at start (years):
35 0.45* 0.62* 1.02* 1.52*
45 0.44* 0.58 0.90 1.34
55 0.41* 0.52 0.78 1.15
65 0.34* 0.43 0.62 0.92
75 0.24* 0.31 0.43 0.63
85 0.14* 0.17* 0.25* 0.35*
Quality adjusted life years gained†
Age at start (years):
35 0.35* 0.48* 0.80* 1.19*
45 0.33* 0.44 0.70 1.04
55 0.30* 0.39 0.59 0.89
65 0.24* 0.31 0.46 0.70
75 0.17* 0.21 0.32 0.47
85 0.09* 0.12* 0.18* 0.26*
*Categories of patients not generally represented in the heart protection study.
†Values adjusted for age specific and sex specific health related quality of life.
All results discounted at 3.5% per annum.
Table 6 Cost effectiveness of full compliance with lifetime use of generic 40
mg simvastatin daily projected beyond the population of the heart protection
study
Five year risk of major vascular event at start of
treatment
5% 10% 20% 40%
Cost (£) per life year gained
Age at start (years):
35 450* −360* −1070* −1610*
45 330* −360 −940 −1240
55 400* −210 −680 −830
65 660* 50 −380 −450
75 1180* 450 −40 −110
85 2460* 1280* 490* 310*
Cost (£) per quality adjusted† life year gained
Age at start (years):
35 580* −460* −1370* −2060*
45 430* −480 −1210 −1600
55 550* −280 −900 −1070
65 930* 70 −510 −590
75 1740* 650 −50 −140
85 3740* 1870* 690* 420*
*Categories of patient not generally represented in the heart protection study.
†Adjusted for age specific and sex specific health related quality of life.
Negative figures indicate cost savings. £1=€1.5=$1.9.
Discounted at 3.5% per annum; generic simvastatin at £4.87 per 28 day pack.
For Evaluation Only.
Copyright (c) by Foxit Software Company, 2004 - 2007
Edited by Foxit PDF Editor
for people across a wider age range and at lower risk of vascular
disease than is currently the case.
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What is already known on this topic
Statins reduce major vascular events, largely independent of
a person’s cholesterol concentrations at presentation
Overall risk of vascular disease events (not single risk
factors) determines the absolute benefits of statin therapy
What this study adds
Statins are cost effective well beyond the treatment
thresholds proposed in current UK clinical guidelines
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